Many of the meeting's proteomics presentations concerned not so much mass spec analysis itself as the refinement of processes and workflows leading up to it.
The 141-sample study found the test could identify benign lesions in lung cancer patients with a negative predictive value of between 84 percent and 98 percent.
From research collaborations to corporate acquisitions, attention from the broader scientific community highlighted the field's capabilities and limitations.
The collaboration will explore use of the PCC agents, which are synthetic peptides with functions similar to traditional antibodies, for protein research.
NEW YORK (GenomeWeb) – With a series of recent payor decisions, Integrated Diagnostics now has more than 200 million covered lives for its Xpresys Lung cancer test.
NEW YORK (GenomeWeb) – Integrated Diagnostics said today that recent payor decisions have given it more than 200 million covered lives for its Xpresys Lung cancer test.
